Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
FibroBiologics, Inc. - Common Stock
(NQ:
FBLG
)
0.2637
+0.0037 (+1.42%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about FibroBiologics, Inc. - Common Stock
< Previous
1
2
3
Next >
FibroBiologics Announces Payoff of Outstanding Debt
November 26, 2025
Repayment of convertible promissory notes strengthens balance sheet and eliminates further dilution from conversions
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 25, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 24, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
November 20, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 19, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 19, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 31, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics to Present at Bio-Europe 2025
October 24, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics to Present at the 2025 ThinkEquity Conference
October 14, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
BioVie and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
September 26, 2025
Via
ACCESS Newswire
FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa
September 23, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
September 12, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
September 11, 2025
Pilot studies underway to advance IND-enabling preclinical development
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies
September 10, 2025
Pilot studies have shown encouraging results that are supporting the company’s pre-IND enabling development, marking a critical step toward clinical translation of the Bone Marrow Organoid technology
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
August 27, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
July 31, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
July 28, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
Brag House and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
July 11, 2025
Via
ACCESS Newswire
FibroBiologics to Present at the Advanced Wound Care Summit USA
July 11, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank
July 09, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10
July 07, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
Fathom Holdings and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
July 03, 2025
Via
ACCESS Newswire
FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing
June 16, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics to Present at the BIO International Convention 2025
June 16, 2025
From
FibroBiologics, Inc.
Via
GlobeNewswire
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer
June 09, 2025
Seasoned finance executive brings over 20 years of public company and capital markets experience to support clinical-stage growth
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting
May 16, 2025
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third...
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FibroBiologics Presenting at the ThymUS 2025 Meeting
April 29, 2025
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean
April 11, 2025
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics
April 08, 2025
Located in Houston, Texas, the new facility allows FibroBiologics to expand its research and development efforts utilizing fibroblast-based technology
From
Fibrobiologics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
